functions we used oligonucleotide array analysis of 36000 known genes and ESTs using Affymetrix microarray platforms. dChip software 1.3 was used to determine differential gene expression patterns between HSC536N, a FANC-C deficient cell line (Cw), and its homologue corrected by retroviral insertion of the FANC-C gene (Cneo), under normal culture conditions and after incubation with mitomycin C (MMC) at 100 nM. Under normal culture conditions, 73 genes were consistently induced (Cw > Cneo) and 34 genes were repressed (Cw < Cneo) by greater than 2-fold in Cw compared to Cneo. Among the up-regulated genes were pro-apoptotic genes (CASP1, TMS1); MIC1 (a p53-transcriptionally regulated gene); cyclin G2; HSPA1A; ADA; melanoma antigens and THIF. Included in the group of downregulated genes were FOXO1A (an AFX family member that transcriptionally activates Kip1); p63; annexin V; and CD23 a key molecule for B-cell activation and growth. Among the genes that were differentially expressed in Cw but not in Cneo after incubation with MMC, were HK2 (a key enzyme for glucose metabolism); DDB2 a potential link between p53 and the nucleotide excision-repair apparatus; GADD45A involved in DNA repair and S phase entry, and MIC1. Finally, after incubation with MMC, 156 genes demonstrated consistent differential expression between Cw and Cneo. Among the repressed genes were FOXO1A; p63; annexin V; CD23; and TOSO a negative regulator of apoptosis. Cyclin G2; CASP1; MIC1; ADA; HSPA1A; THIF; melanoma antigens and REDD1 (a transcriptional target of p53 up-regulated following DNA damage involved in regulation of ROS) were at higher levels of expression in Cw after MMC exposure. These preliminary data have enabled us to identify new genes that may be involved in FA pathogenesis. The increased level of expression of genes involved in ROS metabolism (ADA, REDD1, THIF) in Cw underlies the importance of this metabolic pathway in FANC-C. Extrapolation of these results on a "leukemic" tetraploide HSC536N cell line as well as on FANC-A, -G, -D2 deficient cell lines and patient samples are under investigation.
Allogeneic stem cell transplantation (SCT) might be an option in resistant chronic lymphocytic leukemia (CLL) since this disease is known to be sensitive to graft-versus-leukemia (GVL) effects. However, allografting for CLL using conventional conditioning has been associated with an extremely high treatment-related mortality (TRM). In order to avoid toxicity but take advantage of GVL activity, we have studied allotransplantation in CLL using an reduced-intensity conditioning (RIC) regimen containing fludarabine (F) and cyclophosphamide (C). 18 patients with symptomatic CLL relapsing after fludarabine or equivalent high risk features were eligible. Median age was 52 (40-63) years. Previous therapy comprised 3 (1-7) regimens. PBSC grafts were obtained from HLA-identical related (n=14) or unrelated donors (n=4). Conditioning consisted of daily F 30mg/m² and C 500mg/m² over 5 days; GVHD prophylaxis was performed with CSA/short-course MTX or CSA/MMF. In case of unrelated donors, ATG was added. Donor lymphocyte infusions (DLI) were administered from day +100 onwards in case of incomplete chimerism or residual disease. Results: Hematopoietic recovery occurred in all patients with a median time to neutrophil recovery of 15 (7-28) days and a median number of 2 (0-37) transfused platelet units. At least transient partial or complete (>95%) hematopoietic donor chimerism was observed in all 17 patients evaluable for this endpoint (including 3 patients receiving DLI): The probability of being a complete chimera was 44% at 3 months and 93% at 12 months post transplant. Early nonhematological toxicity was very low, and severe acute GVHD occurred in only 2 patients. The 12-month estimate of chronic GVHD was 69% (95%CI 45-93%). With 16 (1-40) months of follow-up, 2-year event-free survival and TRM were 88% and 6%, respectively. Molecular remission as defined by polyclonal consensus primer CDR3 PCR was achieved by 9 of 11 evaluable patients after a median time of 7 (1-11) months post SCT. Conclusions: The RIC regimen used here promises to improve the outcome after allogeneic SCT for poor-risk CLL by reducing TRM while preserving significant GVL activity.
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Sibling and unrelated reduced-intensity conditioned allogeneic transplantation for chronic myeloid leukemia C. Crawley, R. Szydlo, M. Lalanacette, A. Bacigalupo, A. Lange, G. Juliusson, A. Shimoni, A. Nagler, A. Gratwohl, J. Mayer, O. Ringden, J-M Boiron, G. Smith, D. Niederwiesser, J 
. Apperley for the Chronic Leukaemia Working Party of the EBMT
Reduced intensity conditioned (RIC) allografts have been widely adopted in haemopoetic transplant programmes over the last 5 years despite limited evidence of efficacy with the majority of series reporting a variety of diseases and/or small numbers. 39 EBMT centres reporting more than 5 RIC allografts for CML or myeloma between 01/94 and 09/02 were contacted and data on all procedures performed in those centres were collected on a total of 225 transplants. The M:F ratio was 1.6:1 and the median age was 50 yrs (13-66). 134 were matched siblings, 65 were unrelated and the remainder were from mismatched or other related donors. 62% were in 1st CP, 14% 2nd CP, 17% AP and 7% in blast crises. The median time to transplant was 15 months (2 months-21 years). Conditioning regimens included fludarabine (74%), cyclophosphamide (30%), busulphan (41%), melphalan (19%) and campath/ATG (49%). Total body irradiation was used in 17% with a median dose of 2.0 Gy. The source of cells was bone marrow (BM) in 72 patients and peripheral blood stem cells (PBSC) in 152. Median cell doses for BM were 3.8 x10^8 MNC/kg and 5.8x10^6 CD34/kg for PBSC. Neutrophil and platelet engraftment occurred at median of 16 and 17 days respectively and the non engraftment rate was 8%. GvHD prophylaxis consisted of cyclosporin in 50% with additional methotrexate in 45%. Acute GvHD (grade II-IV) occurred in 29.5% but grade III-IV was limited to 8.1%. Chronic GvHD occurred in 72/122 and was extensive in 25.4%.. Chimaerism (>95% donor) was achieved in 80.4% at best but had fallen to 77% at last follow up (data on 107 patients, median follow up 420 days). Overall the treatment-related mortality was at 1 year was 22%. Progression occurred in 39%. With a median follow up of 342 days overall survival at two years was 55%. Factors associated with a poor outcome at 2 yrs were, disease phase 1st CP, 2nd CP or AP/BC survival was 66%, 61%, 21% respectively (p= 0.0001) and time to transplant > 1 yr, 65% vs 44% (p=0.01). Age, donor type, source of cells and the female donor-male recipient combination were not associated with an adverse outcome. There was a trend to worse outcome with male sex (51% vs 61%, p=0.11). This study confirms the feasibility of RIC allografts and the acceptable TRM. The survival at two years is in keeping with conventional allogeneic transplantation despite the older age.
O371
Sibling and unrelated reduced-intensity conditioned allogeneic transplantation for multiple myeloma C. Crawley, R. Szydlo, M. Lalancette, G. Juliusson, A. Shimoni, A. Nagler, T. Ruutu, L. Ades, M. Michallet, A. Urbano-Ispizua, H. Einsele, R. Chopra, A. Zander, H. Greinix, J. Cavenagh, F. Garban, D. Niederwiesser, G. Gahrton, J 
. Apperley for the Chronic Leukaemia Working Party of the EBMT
Reduced intensity conditioned (RIC) allogeneic transplant appears to be an attractive therapeutic option for myeloma particularly in light of the high treatment related mortality associated with conventional allografts. Evidence of efficacy is however lacking, as the majority of series are small and frequently diagnostically heterogeneous. A total of 256 transplants from 40 EBMT centres reporting more than 5 RIC allografts for CML or myeloma between 11/97 and 07/00 were contacted and data on all procedures performed in those centres were collected. The M:F ratio was 1.5:1, median age was 52 years (32-66) and 70% had stage III disease at diagnosis. 194 were matched siblings, 40 were unrelated and 9 were from mismatched or other related donors. At transplant 61% were in partial or complete remission (CR=7.6%) and 29% had evidence of disease progression. The median time to transplant was 20 months (2 months-11 years). Conditioning regimens included fludarabine (95.5%), cyclophosphamide (28%) melphalan (41%) busulphan (19) and Campath/ATG (48%). Total body irradiation was used in 27% at a median of 2.0 Gy . The cell source was bone marrow (BM) in 45 patients and peripheral blood stem cells (PBSC) in 202. The median cell doses of 2.7 x10^8 MNC/kg for BM and 5.2x10^6 CD34/kg for PBSC. Neutrophil and platelet engraftment occurred at median of 14 days and the nonengraftment rate was 5%. GvHD prophylaxis consisted of cyclosporin in 60% combined with methotrexate in 39%. Acute GvHD (grade II-IV) occurred in 31% but grade III-IV GvHD was limited to 11.9%. Chronic GvHD occurred in 77/178 and extensive in 22.7%. Chimaerism (>95% donor) was achieved in 90.5% at best but had fallen to 81.5% at last follow up (data on 119, median follow up 170 days). Progression occurred in 31%. The overall survival at two years was 52%. Factors associated with an adverse 2yr survival were failure to attain CR/PR (42 vs 57% p=0.003) and male recipients with a female donor (37% vs 57%, p=0.009). Patient sex was borderline (M 45%, F 66% p=0.07) as was transplantation more than 1 yr after diagnosis. HLA match, age, cell source and CMV status were not significant. Overall TRM was 23% at one year but was only 9% for patients transplanted within 1 year of diagnosis. RIC allografts are clearly feasible and seem to be associated with a lower TRM than with conventional allografts. The overall survival is respectable compared to conventional allogeneic transplants for myeloma.
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Reduced-intensity conditioning followed by allogeneic transplantation can produce clinical and molecular remissions in relapsed non-Hodgkin's lymphoma P. Corradini, M. Bregni, C. Tarella, A. Olivieri, A. Dodero, L. Farina, F. Zallio, P. Leoni, F. Ciceri, L. Devizzi, F. Benedetti, E. Pogliani, A. Rambaldi, A. Locasciulli, M. Falda, A. Santoro, R. Scime, A.M. Gianni (Milan, Turin, Ancona, Verona, Bergamo, Rome, Palermo, I) Conventional-intensity HSCT has a 50 to 70% incidence of acute GVHD and 40 to 50% non-relapse mortality when used to rescue relapsed non-Hodgkin lymphomas (NHL). In order to decrease the non-relapse mortality, and to investigate the postulated graftvs-lymphoma effect, we employed a reduced-intensity conditioning in 54 relapsed pts: 29 low/intermediate-grade (13 CLL/SLL, 6 MCL, 10 FCL), 25 high-grade (7 T-cell lymphomas, 17 B-cell DLCL, 1 Burkitt). Median age was 50 years (range: 21-66). Before transplant, 53% had a chemosensitive disease. The median time from diagnosis to allograft was 26 months (range: 5-140 months). The median number of previous chemotherapy regimens was 2 (range 1-5); 44% of pts had already failed a previous autograft. After conditioning with thiotepa (10 mg/kg), fludarabine (60 mg/ms) and cyclophosphamide (60 mg/kg), pts received bone marrow (n= 13) or lenogastrim-mobilized peripheral blood cells (n= 41) from HLA-matched (n=51) or oneantigen mismatched sibling donors (n=3). GVHD prophylaxis consisted of cyclosporine A and short course methotrexate. In vivo T -cell depletion, using antithymocyte globulin (N=1) or alemtuzumab (n=2), was performed in pts with one antigen mismatch. All patients engrafted. Acute GVHD occurred in 61% of the pts, and was scored grade I-II in 46% and grade III-IV in 15%. Chronic GVHD developed in 35% of pts. Non-relapse mortality was 11% (infections=2, TTP=1, multiorgan failure=2, aGVHD=1). At a median follow-up of 450 days (range 35 -1440 days), 42 pts (77%) are alive: 36 in CR, and 6 in P R. The actuarial 2-year OS and PFS for the whole group were 79% and 75% respectively. Pts treated with a previous autograft did not show inferior survival when compared to pts receving previous conventional chemotherapy (OS 55% vs 71%, P=0.10). Overall survival at 2-year was 90% for pts with chemosensitive disease and 40% for patients with refractory disease (P=0.001). In 20 of 29 pts with low/intermediate-grade NHL, a molecular marker based on bcl-2, bcl-1 or IgH genes was generated. Among pts in clinical CR, 17 were suitable for PCR monitoring of residual disease: 11 pts are in continuous molecular remission and none of them relapsed so far (median molecular follow-up: 425 days, range 90 -850). In conclusion, allo HSCT with reduced conditioning has a low non-relapse mortality, and can produce durable clinical and molecular remissions in relapsed NHL.
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Reduced-intensity conditioning (thiotepa + cyclophosphamide) and rabbit anti-thymocyte globulin for alternative donor transplants T. Lamparelli, C. di Grazia, R. Oneto, B. Bruno, D. Occhini, F. Gualandi, S. Bregante, A.M. Raiola, A. Dominietto, V. Galbusera, E. Tedone, F. Frassoni, M.T. van Lint, A. Bacigalupo (Genoa, I) Background. Many reduced intensity regimens have been described, though few have been compared with the conventional dose programs. Objective. To compare a reduced intensity regimen of thiotepacyclophosphamide (10 mg/kg +100 mg/kg) (THIO10-CY100) with the same combination given at conventional doses (15 mg/kg + 150 mg/kg) (THIO15-CY150) as conditioning in 69 patients undergoing an alternative donor hemopoietic stem cell transplant (HSCT). Methods. All patients received GvHD prophylaxis with antithymocyte globulin (ATG) (Thymoglobulin, Sangstat) 7.5-15 mg/kg , Cyclosporin A from day -7 a nd short course methotrexate (MTX). The diagnosis was CML (n=33), acute leukemias (n=17), lymphoproliferative disorders (n=9), other (n=10); 78% of the patients had advanced disease. The donor was either one antigen family mismatched (n=28) or unrelated (n=41). The source of stem cells was marrow in the majority (91%). The age of the patients was significantly higher in the reduced THIO10+CY100 (median 43, range 35-64) as compared to the conventional THIO15+CY150 (median 34, range 17-52) (p=0.005). The median follow up is 158 days (15-2260). Results. The reduced THIO10+CY100 had less severe acute GvHD (4% vs 25%, p=0.01), less chronic GvHD (9% vs 29%,p=0.1), less transplant mortality (23% vs 46%, p=0.08) better survival (67% vs 35%, p=0.01). The reduced THIO10+CY100 had less deaths due to GvHD (5% vs25%) and infections (4% vs 14%) and comparable rejections (5% vs 4%). The actuarial transplant mortality at 1 year is 24% vs 50% (p=0.04). The relapse is comparable (35% vs 33%, p=0.8) but will require further follow up.
S58
Conclusions. This study indicates that THIO10+CY100+ATG allows engraftment with a low risk of GvHD in adults up to the age of 64, undergoing an alternative donor transplant . This regimen is better tolerated when compared to the same agents given in conventional doses.
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Allogeneic hematopoietic transplantation from HLA-identical siblings: independent prognostic effect of age, diagnosis, and reduced-intensity conditioning D. Valcarcel, C. Canals, R. Martino, A. Sureda, A. Altes, J. Briones, M. A. Sanz, R. Parody, M. Gomez, M. Constans, L. Villela, S. Brunet, J. Sierra (Barcelona, E) Allogeneic HSCT is potentially curative for hematological and non-hematological malignancies. We analyzed the factors associated with transplant-related mortality (TRM) in 167 adult patients, consecutively receiving a HSCT from an HLA identical. Patients were transplanted at our institution between January 1995 and March 2002. Median age was 45 years (range, 16-66) and sex distribution was 109 males and 58 females. Most frequent diagnoses were acute leukemia or myelodysplasia (n=70), myeloproliferative dysorders (n=30) and lymphoproliferative syndromes (n=59). The stem cell source was bone marrow in 30 cases (T-cell depleted in 9) and peripheral blood in 137 transplants (T-cell depleted in 36). STAND conditioning was administered in 103 patients, while reducedintensity conditioning (RIC) regimens were used in the remaining 64. Sixty-two patients (37%) were transplanted in early phase of their disease and 105 (63%) in more advanced stages. Twentyeight patients (17%) had received a previous autologous transplantation, 22 of the RIC group (34%) and 6 of the STAND group (6%) [p<0.01]. Fifty patients in the RIC group (78%) were >45 years old as compared with 44 (43%) in the STAND group [p<0.01]. After a median follow-up for surviving patients of 19 months (3-94), the cumulative incidence of TRM at 2 years in the whole group was 27% (95%CI: 21-35), with an estimated overall survival (OS) at 2 years of 55% (95%CI: 47-63). In multivariate analyses four variables were identified as adverse prognosis factors for TRM: age > 45 years, RR 5.7 (2.7-12) p<0.001; STAND vs RIC, RR 4.9 (2.2-10.9) p<0.001; non T-cell depletion, RR 2.8 (1.3-5.9) p=0.006; and 2nd transplant, RR 2.5 (1.1-5.3) p=0.02. The 2-year incidence of TRM for patients > 45 years was 47% (95%CI: 34-65) in the STAND group vs 29% (95%CI: 18-47) in the RIC group (p=0.07). For patients younger than 45 years, these figures were 16% (95%CI: 9-29) vs 0%, respectively (p=0.1). No differences were found in the risk of post-transplant disease progression between STAND and RIC groups. In multivariate analyses 3 variables had a deleterious effect on OS: age > 45 years, RR 2.8 (1.6-4.9) p<0.001; STAND vs RIC RR 2.7 (1.4-5.2) p=0.002; and diagnoses other than CML RR 2.4 (1.2-5.1) p=0.01. This study shows that RIC allografts lead to an improvement in the 2-year OS due to a reduction of TRM.
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Conditioning with fludarabine and targeted busulfan to achieve stable engraftment with reduced toxicity from HLAmatched related and unrelated donors in high-risk patients with myeloid leukemia and myelodysplastic syndrome M. Bornhäuser We have tested a regimen combining fludarabine and targeted doses of busulfan to replace cyclophosphamide and facilitate donor engraftment with reduced toxicity. The conditioning therapy consisted of intravenous fludarabine 30 mg/m2 daily from day -9 to day -6, and oral busulfan given at 1 mg/kg x 16 every 6 h from day -5 to day -2, with doses adjusted to target plasma levels of 900 ± 100 ng/ml at steady state. Detailed pharmacokinetic monitoring of fludarabine plasma levels was performed. Prophylaxis for graft-versus-host disease was with cyclosporine and methotrexate. Forty-two patients with high-risk CML (n=4) or MDS (n=38) were enrolled. The median patient age was 52 (range 12-65) years. Mobilized blood stem cells were obtained from HLA-compatible siblings (n=16) or unrelated donors (n=26). Donor chimerism was analyzed in sorted CD33+ myeloid cells and CD3+ T cells. No accumulation of F -Ara-A was observed over the 4 -day administration period. There was no significant association of mean F -Ara-A AUC and time to neutrophil and platelet engraftment or level of T cell chimerism on day 75. Thirty-five of 40 patients achieved the prescribed busulfan target range of 800-1000 ng/ml. Engraftment was achieved in all patients, and the day-100 regimen-related mortality was 7%. On day 75, chimerism was tested in 31 patients: all showed donor type in 26% to 100% (median 100%) of the granulocytes (CD33+) and 35% to 95% (median 75%) of the T (CD3+) cells. The patient with 26% donor myeloid cells experienced hematological relapse of CMML shortly thereafter. At one year, chimerism was tested in 12 patients: donor type was between 91% and 100% (median 99.5%) for granulocytes and between 28% and 100% (median 98%) for T cells. With a median follow-up of 13 (range 9-22) months, the one-year probabilities of overall survival and relapse-free survival were 52.6% and 43.5%, respectively. These data indicate that the combination of fludarabine and targeted busulfan is sufficiently immunosuppressive to facilitate engraftment of blood stem cells from HLA-matched siblings or unrelated donors. Plasma levels of fludarabine (F-Ara-A) did not correlate with clinical end-points. Intracellular measurements might be more meaningful. Mixed T cell chimerism was observed in he first three months after transplantation. The results of this study suggest to test the regimen of fludarabine and targeted busulfan prospectively in standard risk patients with myeloid malignancies.
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Long-term follow-up of 92 hematopoietic stem cell transplantation patients after non-myeloablative conditioning regimens: a study from the SFGM-TC Registry M. Michallet, Q. Lé, K. Bilger, F. Garban, A. Huyn, D. Blaise, N. Milpied, P. Bordigoni, M. Kuentz, A. Sadoun, J.Y Cahn, G. Socié, A. Michallet, F. Nicolini, C. Vigouroux, A. Pigneux, J 
.M Boiron on behalf of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
In a previous study we have analyzed 92 allogeneic hematopoietic stem cell (HSC) transplantations after non myeloablative regimens which were reported to the SFGM-TC registry (JCO 2001 19:3340-9) . Initial diagnosis was chronic lymphoid diseases (LD) (n = 22), multiple myeloma (MM) (n = 14), acute leukemia (AL) and myelodysplasia (MDS) (n = 41), chronic myelogenous leukemia (CML) (n = 12), and solid tumors (n = 3), 49 patients have been transplanted in progressive disease. Seventy-nine patients have engrafted (52 males, 27 females) and with a median follow-up of 8 months the overall survival was 32% ± 12% at 18 months. We decided to update this series and with a median follow-up of 45.5 months, the probability of 3 -year overall survival is 29% [20.4-40.9] . In a multivariate analysis, we found a significant association between survival and diagnosis in favour of lymphoid diseases and CML [LD+CML vs (n=8), CML (n=5), MM (n=2), AL+MDS (n=5), and prior conditioning 7 patients (35%) were in progressive disease. Among these 20 alive patients, 16 (80%) presented a chronic GVHD (7 limited and 8 extensive) of whom 12 (75%) have received PBSC as HSC source and 16 patients (80%) are in continuous complete remission (14 among them presented a cGVHD). Regarding cGVHD incidence, we observed a trend in favour of ATG during conditioning [19/44 (43%) Maccario, A. Cometa, A. Moretta, P. Comoli, D. Montagna, M.A. Avanzini, M. Labirio, G. Giorgiani, M. Zecca, F. Locatelli (Pavia, I) Aim of the study is to investigate new strategies of ex vivo manipulation of alloantigen-specific immune response, to obtain populations of cells substantially and selectively devoid of alloreactivity and, therefore, apt to be employed for accelerating immune reconstitution after T cell depleted HSCT, without augmenting the risk of GVHD. To this end, PBMC of a responder individual were cultured with irradiated stimulator PBMC of an unrelated, HLA-diverse subject. After 72-hour culture, CD69+ cells, including both CD4+ and CD8+ T lymphocytes, were depleted from MLC. CD69-depleted populations, together with fresh stimulator PBMC were then cultured for further 12 days in the presence of CTLA4-Ig (treated MLC). Cell recovery of treated-MLC was 25-30% of that obtained from control (ctrl) MLC. Effector cells recovered from treated and ctrl MLC were tested in secondary MLC, in the absence of CTLA4-Ig. Results of secondary MLC, obtained from 2 experiments, demonstrated that: 1) proliferative activity (+3 and +7 day-culture) of effector cells obtained from treated MLC, was absent or very low, if compared with effector cells of ctrl MLC; 2) cytotoxic activity directed towards allogeneic stimulator target cells, measured after 10-day culture in the presence of exogenous IL-2 (5 U/ml at day +3 and +6), was undetectable for treated MLC and ranged between 35-50% of specific lysis for ctrl MLC; 3) capacity to produce cytokines (measured by 48-hour ELISPOT), particularly IFN-gamma and IL-12, was substantial in ctrl MLC and absent in treated MLC. Other cytokines (IL-2, IL-4, IL-5, IL-10) were comparably low in both conditions. Cell recovered from treated MLC after 10-day secondary MLC in the presence of added IL-2 included a high percentage (> 70%) of CD4+CD25+ lymphocytes, most expressing CTLA4, while this subset was < 40% in ctrl MLC with a minority expressing CTLA4. Altogether, these preliminary data suggest that effectors from treated MLC are strongly depleted in alloreactive cytotoxic cells, while they are enriched in a subset of CD4+CD25+ cells, recently described to display regulatory/suppressive function of immune response. Experiments are in progress to define the immunocompetence of effector cells obtained from treated MLC towards antigens other than alloantigens (e.g. microbial antigens), and to investigate the possibility that selected stimuli, such as virus antigens might reverse the state of alloantigen-specific unresponsiveness.
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Microscopic chimerism in lymphatic organs persists after vascularized bone marrow transplantation Z. Akdogan, F. Quatra, R. De Jesus, D. Lowenberg, L.A. BaxterLowe, D. Brooks, H. Buncke (San Francisco, USA) Vascularized bone marrow transplantation has been attempted in recent times suggesting that transplantation of hematopoietic stem cells with their own microenviroment may lead to better results. Research has mainly focused on the rate and speed of repopulation in bone marrow depleted recipients or on the induction of chimerism in association with different immunosuppressive agents. Our objectives were to evaluate the early events associated with rejection of a vascularized bone marrow transplant including any transient condition of chimerism in the peripheral blood or in the lymphatic organs of the recipients. Methods: Lewis rat recipients received vascularized (femur) and non-vascularized bone marrow transplants and/or vascularized/nonvascularized thymus transplants from Brown Norway recipients. Blood was subsequently drawn at scheduled intervals to be processed for double staining with a TcRalpha/beta monoclonal antibody PE-conjugated (R73) and an MHC-I donor specific monoclonal antibody FITC-conjugated (RT1-Ac) for assessment of hematopoietic chimerism. Previous studies at our institution showed that immunohistochemistry is a sensitive mean to study microchimerism in the thymus and spleen, with the addition of a morphological picture of ongoing interactions between donor-derived cells in the host environment. Frozen sections of thymus and spleen were therefore harvested and processed for staining with the biothinilated donor-specific antibody (RT1-Ac). Results: Although hematopoietic chimerism in the peripheral blood quickly disappeared with ongoing rejection in all the experimental groups, however under certain conditions donorderived cells persisted in the lymphatic organs and survived well beyond complete rejection of the vascularized femur/thymus transplant. Conclusion: Prolonged survival of donor-derived cells without immunosuppressive treatment suggests a form of dynamic balance in the interaction between host and recipient of a vascularized bone marrow transplant. It is possible that rapid recovery of the transplant with almost-immediate return of function may help overcoming host reactions allowing a limited number of cells to survive. Further characterization of the cell populations involved is underway and could help understand the frequent occurrence of tolerance in rat models of vascularized bone marrow/limb transplantation.
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Purified donor KN-cell infusion to revert impending rejection after haplo-identical stem cell tansplantation J. Passweg, D. Tsakiris, S. Meyer-Monard, A. Buser, D. Heim, A. Gratwohl, A. Tichelli (Basel, CH) Donor lymphocyte infusions may be used to treat relapse in improve engraftment but these are usually avoided after haploidentical SCT because of GvHD risks. Recent experimental data have shown, that alloreactive NK cells may promote engraftment without causing GvHD. A 25 year old female patient received a haploidentical stem cell transplant to treat a first refractory relapse of AML M4 treated initially with chemotherapy and autologous SCT. Conditioning was with VP-16, cyclophosphamide, TBI and ATG, posttransplant immunosuppression consisted of a 14 day course of cyclosporine and a 10 day course of OKT3 to promote engraftment. She received 35 x 10e6/kg highly purified CD34+ cells (0.55 x 10e5/kg CD3+cells) from her haplo-identical father. The HLA typing (patient: HLA Cw07, Cwx; donor: HLA Cw07, Cw04) was indicaive of NK-cell alloreactivity between donor and
